Abstract:A novel target compound 1a, with an aminosulfonyl group instead of the 2‐hydroxypropan‐2‐yl moiety in adavosertib was synthesized and showed improved Wee1 enzyme inhibitory activity and metabolic stability. However, it exhibited inferior cellular activities in MDA‐MB‐231 cell growth inhibition and Wee1 substrate phosphorylation inhibition compared to adavosertib, which may be attributed to its low permeability. For an analog‐based design of novel Wee1 inhibitors, we profiled in vitro ADMET and in vivo PK properties of adavosertib. Based on the properties of adavosertib, we aimed to improve its metabolic stability by designing a novel target compound 1a with an aminosulfonyl group instead of the 2‐hydroxypropan‐2‐yl moiety in adavosertib. Derivatives of target compound 1a were synthesized and evaluated for Wee1 enzyme inhibition and liver microsomal phase I stability. We identified compound 1a as a sub‐nanomolar Wee1 inhibitor and 10 additional compounds with one‐digit nanomolar Wee1 inhibitory activity, among which seven compounds including 1a exhibited improved metabolic stabilities compared with adavosertib. However, MDA‐MB‐231 cell growth inhibitory activities of all synthesized compounds and Wee1 substrate phosphorylation inhibitory activities of selected compounds were inferior to adavosertib overall. Moreover, the representative compound 1a exhibited low permeability, which may be the reason for the low cellular activities of compound 1a.

Discovery of Pyrido[4,3-d]pyrimidinone Derivatives as Novel Wee1 Inhibitors

Advanced Design, Synthesis, and Evaluation of Highly Selective Wee1 Inhibitors: Enhancing Pharmacokinetics and Antitumor Efficacy

Discovery of Potential WEE1 Inhibitors Via Hybrid Virtual Screening

Synthesis and biological evaluation of (2‐aminosulfonylpyridin‐6‐yl)pyrazolopyrimidinone derivatives as Wee1 inhibitors for cancer treatment

Design, Synthesis and Biological Evaluation of Thienopyridinones As Chk1 Inhibitors

Inhibitors of cell cycle checkpoint target Wee1 kinase – a patent review (2003–2022)

Discovery of Pyrrolopyrimidinone Derivatives As Potent Pkmyt1 Inhibitors for the Treatment of Cancer

Discovery of (R)-5-((5-(1-methyl-1h-pyrazol-4-yl)-4-(methylamino)pyrimidin-2-yl)amino)-3-(piperidin-3-yloxy)picolinonitrile, a Novel CHK1 Inhibitor for Hematologic Malignancies.

Structural Basis of Wee Kinases Functionality and Inactivation by Diverse Small Molecule Inhibitors

Discovery of pyrido[3,2- d ]pyrimidin-6(5 H )-one derivatives as checkpoint kinase 1 (CHK1) inhibitors with potent antitumor efficacy

Design, Synthesis, and Biological Evaluation of Pyrido[2,3- d ]pyrimidin-7(8 H )-one Derivatives As Potent USP1 Inhibitors

Discovery and optimization of thieno[3,2- d ]pyrimidine derivatives as highly selective inhibitors of cyclin-dependent kinase 7

Discovery of Novel 5-(Pyridazin-3-yl)pyrimidine-2,4(1 H,3 H)-dione Derivatives as Potent and Orally Bioavailable Inhibitors Targeting Ecto-5'-nucleotidase

Design, synthesis, and biological evaluation of Wee1 kinase degraders

Discovery of Tetrahydropyrazolopyrazine Derivatives as Potent and Selective MYT1 Inhibitors for the Treatment of Cancer

Discovery of Pyrazole-Thiophene Derivatives As Highly Potent, Orally Active Akt Inhibitors.

Design, synthesis and biological evaluation of 4-(indolin-1-yl)-6-substituted-pyrido[3,2- d ]pyrimidine derivatives as Mnk1/2 inhibitors

Discovery of pyrazolo[3,4-b]pyridine derivatives as novel and potent Mps1 inhibitors for the treatment of cancer

Structure-activity relationships of Wee1 inhibitors: A review

Identification of a Rhodium(iii) Complex As a Wee1 Inhibitor Against TP53-mutated Triple-Negative Breast Cancer Cells.

Discovery of Novel [1,2,4]Triazolo[1,5- a]pyrimidine Derivatives as Novel Potent S-Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer